WearLinq Raises $19 Million to Scale Wireless Clinical‑Grade Cardiac Monitoring Nationwide
WearLinq, the San Francisco‑based medical technology company developing advanced wearable cardiac monitoring solutions, has raised $14 million in a Series A funding round along with an additional $5 million in venture debt financing, propelling the scaling of its eWave wireless clinical‑grade cardiac monitor nationwide. The company’s innovative approach to continuous heart rhythm monitoring, designed to improve early detection of cardiovascular conditions and deliver actionable data to clinicians, has attracted a broad roster of investors and positions WearLinq for rapid growth in a large and underserved market.
The Series A financing was led by AIX Ventures, a venture firm focused on early‑stage technology ventures, demonstrating deep confidence in WearLinq’s strategy to expand access to real‑time cardiac health insights. Participation in the round came from several prominent investors, including SpringTide Ventures, Berkeley Catalyst Fund, Lightscape Partners, Solasta, Alumni Ventures, Amino Capital, AngelSchool.vc, LDV Partners, Maliam, XB Ventures, Celtic House Asia Partners Health, Device of Tomorrow Capital, NYX Ventures Partners, and SmartLink Partners. This deep and diversified investor base reflects strong belief in WearLinq’s potential to transform cardiac care through wearable technology.
Founded in 2019 by Konrad Morzkowski, who serves as CEO, WearLinq has quickly emerged as a leader in ambulatory cardiac monitoring by combining cutting‑edge hardware and cloud‑enabled data reporting to deliver continuous, multi‑lead electrocardiogram (ECG) data outside of traditional clinical settings. The company’s flagship device, eWave, is a wireless, six‑lead ECG wearable that pairs with a user’s smartphone to transmit real‑time cardiac data and produce clinician‑ready reports in under 48 hours. Designed for comfort and convenience, eWave can operate for more than five days on a single charge and is intended to support arrhythmia detection and broader cardiac monitoring use cases.
The $14 million Series A and $5 million venture debt infusion will enable WearLinq to accelerate commercialization of eWave across the United States, expand clinical partnerships, and enhance its technology platform for broader diagnostic applications over time. The funding also comes at an important inflection point for the company, which has already received FDA 510(k) clearance for the eWave monitor, enabling its integration into existing clinical care pathways. By equipping clinicians with continuous cardiac data, WearLinq aims to reduce undiagnosed heart conditions and improve intervention timing, potentially saving thousands of lives annually.
In addition to its fundraising success, WearLinq has made strategic moves to broaden its clinical footprint. In 2024, the company acquired AMI Cardiac Monitoring, LLC, an independent diagnostic testing facility with over three decades of expertise in ambulatory cardiac monitoring. This acquisition expanded WearLinq’s ability to provide comprehensive diagnostic services nationwide, leveraging AMI’s clinical infrastructure alongside WearLinq’s innovative technology.
Investor backing for WearLinq aligns with growing demand for remote and continuous health monitoring solutions, particularly in cardiovascular care where early detection and data continuity are critical. Cardiovascular disease remains a leading cause of mortality globally, and technologies that facilitate long‑term, patient‑centric monitoring are gaining traction in both clinical and consumer health segments. WearLinq’s eWave system — with its FDA clearance, wearable design, and smartphone integration — positions the company to capitalize on this trend while advancing clinical outcomes.
WearLinq’s leadership has emphasized that this funding will not only drive product deployment but also support expansion of clinical applications and partnerships with health systems, insurers and clinicians. By enhancing its distribution network and continuing to innovate on cardiac monitoring capabilities, the company plans to broaden access to its technology and serve a wider range of patients who can benefit from continuous heart rhythm tracking outside traditional medical environments.
Market analysts and investors view WearLinq’s progress as indicative of the broader growth potential in digital health and remote cardiac monitoring sectors. With a compelling combination of regulatory clearance, clinical utility, and strong investor support, WearLinq is positioned to play a significant role in reshaping how cardiac health is monitored and managed, accelerating the shift toward proactive and data‑driven care that can improve patient outcomes nationwide.
